BBIO BridgeBio Pharma, Inc.
Price Chart
Executive Summary
BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 shares of common stock valued at approximately $1.78 million. The filing discloses that the proposed sale will be executed through the Kumar Haldea Revocable Trust and/or Family Irrevocable Trust, both of which Kumar manages. The filing references a pre-existing Rule 10b5-1 trading plan, and Kumar has sold similar blocks of 20,000 shares per trade nearly every week since mid-March across these trusts — these sales are routine and pre-planned, not a reactive insider signal.
Actionable Insight
This Form 144 is a continuation of a high-cadence but mechanically pre-planned 10b5-1 selling program by the CEO in two trusts. The predictable weekly pace and fixed lot size suggest a liquidity or tax-planning strategy rather than a reactive signal. No earnings or binary catalyst is imminent (next quarterly filing would be ~August 2026). Traders should not read this as bearish — the pattern has been in place for over two months. No action warranted.
Key Facts
- CEO Neil Kumar filed Form 144 proposing to sell 26,103 shares of BBIO common stock on or after May 21, 2026.
- Estimated proceeds of the proposed sale are $1,780,746.66 based on the filing date price of ~$68.22/share.
- The filing notes that the sale will be executed under pre-existing Rule 10b5-1 trading plans for the Kumar Haldea Revocable Trust and Family Irrevocable Trust.
- Since mid-March 2026, Kumar has sold 20,000-share blocks (fixed lots of ~$1.3-1.5M) approximately weekly across both trusts — this filing is a continuation of that cadence.
- Recent insider activity totals $2.0M in sells over the past 30 days across 3 transactions, consistent with the pattern.
- Market cap is $13.4B; the proposed sale represents only ~0.002% of shares outstanding.
Financial Impact
Proposed sale of 26,103 shares at ~$1.78M, representing approximately 0.002% of market cap — immaterial in absolute terms.
Risk Factors
- Insiders using 10b5-1 plans can still cancel or modify them; a persistent high-volume sell program could eventually signal fading conviction if fundamentals deteriorate.
- The $13.4B market cap is supported by 97% analyst buy ratings; any pipeline setback could make routine insider selling look more opportunistic in hindsight.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-004909 |
| Document: 0001950047-26-004909-index.html | 0001950047-26-004909 |
| Document: 0001950047-26-004909.txt | 0001950047-26-004909 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
17d ago
|
Press Release
| $66.44 $63.88 | ▼ −3.85% | ▼ −5.06% | $66.80 (+0.54%) |
|
May 26, 2026
17d ago
|
Insider Cluster
| $66.44 $65.48 | ▲ +1.44% | ▲ +1.91% | $66.80 (−0.54%) |
|
May 21, 2026
22d ago
|
144
| $69.12 $65.36 | ▼ −5.44% | ▼ −7.10% | $66.80 (−3.36%) |
|
May 19, 2026
24d ago
|
Insider Cluster
| $68.22 $68.45 | ▲ +0.34% | ▼ −1.47% | $66.80 (−2.08%) |
|
May 12, 2026
4w ago
|
Press Release
| $65.95 $65.32 | ▼ −0.96% | ▼ −1.03% | $66.80 (+1.29%) |
|
May 11, 2026
4w ago
|
Press Release
| $64.68 $65.32 | ▲ +0.99% | ▲ +1.07% | $66.80 (+3.28%) |
|
May 8, 2026
5w ago
|
S-3ASR
| $67.39 $69.66 | ▲ +3.37% | ▲ +1.90% | $66.80 (−0.88%) |
|
May 7, 2026
5w ago
|
Press Release
| $67.39 $69.66 | ▲ +3.37% | ▲ +1.90% | $66.80 (−0.88%) |
|
May 6, 2026
5w ago
|
Press Release
| $68.09 $65.95 | ▼ −3.14% | ▼ −4.27% | $66.80 (−1.89%) |
|
May 5, 2026
5w ago
|
Press Release
| $68.78 $65.95 | ▼ −4.11% | ▼ −6.10% | $66.80 (−2.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access